--- title: "Abivax launches $600,000,000 offering of American Depositary Shares" url: "https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-30" section: "Financings" tickers: "EURONEXT:ABVX" source: "https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm" summary: "Abivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000," --- By the aibio.space news desk. Sources - [Abivax SA 424B5 (2026-06-30)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm) - [d111359d424b5.htm](https://www.sec.gov/Archives/edgar/data/1956827/000119312526294491/d111359d424b5.htm) - [Abivax SA 20-F (2026-03-23): business](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm) - [Abivax SA financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) [ABVX](https://aibio.space/companies/abivax/) 2026-06-30 # Abivax launches $600,000,000 offering of American Depositary Shares Tickers [ABVX](https://aibio.space/companies/abivax/) Abivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results. ## Key facts - **Company**: Abivax SA (EURONEXT: ABVX) - **News type**: Financings - **Primary source**: [Abivax SA 424B5 (2026-06-30)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm) *Traders on the NYSE floor, 1963. Photo: Thomas J. O'Halloran, public domain, via Wikimedia Commons. The picture shows the field, not the companies named.* ## The offering Abivax SA (Nasdaq and Euronext Paris: [ABVX](https://aibio.space/companies/abivax/)) launched a public offering of American Depositary Shares on June 30, 2026, in a preliminary prospectus supplement for $600,000,000. That document left the share count, price and proceeds blank. Each ADS represents one ordinary share. The final supplement sets the terms. Abivax is selling 6,400,000 ADSs at $125.0000 each, $800,000,000 in total. Underwriting discounts and commissions are $5.9375 per ADS, or $38,000,000, which leaves $119.0625 per ADS, or $762,000,000, before expenses. The company estimates net proceeds of approximately $759.8 (€666.8) million. The underwriters can buy up to 960,000 more ADSs at the offering price on or before the initial settlement date, and with that option the company estimates net proceeds of approximately $874.1 (€767.1) million. Delivery is expected on or about July 6, 2026, and the depositary is Citibank, N.A. ## Banks The joint bookrunning managers are Leerink Partners, Morgan Stanley, Piper Sandler and Guggenheim Securities. LifeSci Capital is a bookrunning manager and Van Lanschot Kempen is lead manager. The cover page does not say which bookrunner leads, and it names no law firm. ## Why the price moved The preliminary filing gives the June 29, 2026 last reported sale price as €83.30 per ordinary share in Paris and $96.15 per ADS on Nasdaq. The final filing gives June 30 prices of €115.50 and $133.26. The $125.0000 offering price is above the first Nasdaq price and below the second. The final supplement explains the gap. On June 29, 2026 the company announced positive topline results from Part 2 of its Phase 3 ABTECT 44-week maintenance trial of obefazimod in ulcerative colitis. Among induction non-responders on 50 mg (N=148), clinical remission at Week 44 was 37.2% and clinical response 61.5%. On 25 mg (N=81) the figures were 23.5% and 50.6%. These are exploratory endpoints. ## The safety record The safety table is less tidy than the headline. Of 447 patients on 50 mg, 307 (68.7%) had a treatment-emergent adverse event and 27 (6.0%) stopped the drug for one. On 25 mg, 21 of 186 (11.3%) stopped. One patient on 25 mg died of a pulmonary embolism that the investigator judged unrelated. Four non-melanoma skin cancers were reported, two in each arm, and two other malignancies appeared in the 50 mg arm. Investigators judged one basal cell and one squamous cell case probably related to the drug. The company says exposure-adjusted rates in the combined active arms sit within published reference ranges for ulcerative colitis. In Phase 3 maintenance that is 0.56 per 100 patient-years for malignancies other than skin cancer, against a 0.30 to 0.70 range. For the 50 mg arm alone the rate is 0.91. For skin cancers the combined rate is 1.26, against a range of 0.70 to 1.40. ## Dilution and finances The supplement starts from 79,694,535 ordinary shares outstanding as of March 31, 2026, adjusted for 403,347 ADSs issued in a royalty certificate repurchase. After the offering, 86,094,535 ordinary shares will be outstanding, or up to 87,054,535 if the option is exercised in full. The repurchase, agreed May 4, 2026, cost $90.0 million, $45.0 million in cash and $45.0 million in shares. The annual report on Form 20-F, filed March 23, 2026, shows a net loss of €336.1 million for 2025, up from €176.2 million. Research and development expense was €177.8 million, and cash used in operations was €161.1 million, against €154.1 million. Year-end cash and cash equivalents were €516.7 million, up from €144.2 million, with short-term investments of €21.4 million. ## Use of proceeds and next steps Abivax says it will use the proceeds for potential US commercialization of obefazimod, clinical research and development in ulcerative colitis and Crohn's disease, and general corporate purposes. The company says it expects to submit a New Drug Application to the FDA in the fourth quarter of 2026. The Crohn's disease Phase 2b trial has a planned top-line induction read-out in the fourth quarter of 2026. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ABVX Abivax SA EURONEXT · France Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Abivax launches $600,000,000 offering of American Depositary Shares", 2026-06-30, https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/